Related Experiment Video
Updated: Sep 13, 2025

05:58
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
3.1K
Single-Cell Transcriptomics: Technical Advances, Applications and Challenges in Cancer Drug Discovery
Yueying Yang1, Lingyu Meng1, Teng Zhang1
1Department of Biomedical Engineering, School of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Current Cancer Drug Targets
|August 4, 2025
Summary
Single-cell RNA sequencing offers deep insights into tumor heterogeneity for cancer drug discovery. This technology accelerates the identification of drug targets and personalized treatment strategies.
Area of Science:
- Oncology
- Genomics
- Biotechnology
Background:
- Single-cell RNA sequencing (scRNA-seq) is a powerful technology for analyzing gene expression at the individual cell level.
- Tumor heterogeneity presents a significant challenge in cancer drug discovery and treatment.
- Understanding cellular heterogeneity is crucial for identifying novel therapeutic targets and predicting drug responses.
Purpose of the Study:
- To provide a comprehensive overview of single-cell RNA sequencing technology.
- To highlight the applications of scRNA-seq in cancer drug discovery.
- To discuss challenges and future directions of scRNA-seq in oncology.
Main Methods:
- Review of existing literature on single-cell RNA sequencing.
- Analysis of scRNA-seq applications in identifying tumor heterogeneity.
- Exploration of scRNA-seq's role in drug target identification and response prediction.
Main Results:
- scRNA-seq provides high-resolution gene expression profiles, revealing cellular heterogeneity.
- This technology aids in identifying specific cell subpopulations and their molecular pathways.
- Applications include discovering new drug targets and predicting patient response to therapies.
Conclusions:
- Single-cell RNA sequencing is revolutionizing cancer drug discovery by enabling a deeper understanding of tumors.
- It facilitates the acceleration of new anti-cancer drug development.
- Future directions aim to enhance clinical translation for personalized oncology treatments.

